Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 65 years of age, inclusive, at the time of informed consent with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) for Schizophrenia and Psychotic Disorders Studies~* Would benefit from hospitalization or continued hospitalization for treatment of a current acute relapse of schizophrenia at trial entry~* Are experiencing an acute exacerbation of psychotic symptoms and marked deterioration of usual function as demonstrated by all of the following:~* Positive and Negative Syndrome Scale (PANSS) Total Score of ≥ 80~* Score of ≥ 4 on two or more of the following PANSS items at screening: hallucinatory behavior, unusual thought content, conceptual disorganization, or suspiciousness~* Clinical Global Impression - Severity of Illness Scale (CGI-S) score ≥ 4 (moderately ill)~Exclusion Criteria:~* Are presenting with a first episode of schizophrenia based on the clinical judgment of the investigator~* Have been hospitalized \> 21 days for the current acute episode at the time of the baseline visit~* Have a current DSM-IV-TR Axis I diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other cognitive disorders; also borderline, paranoid, histrionic, schizotypal, schizoid, antisocial personality disorders or mental retardation.~* Improvement of ≥ 20% in total PANSS score between the screening and baseline assessments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
- Aripiprazole (Type: EXPERIMENTAL): Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).